Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 2/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988968 | 1.00 | SIGMAR1 (0.36) | SIGMAR1HCRTR2HCRTR1LMNAHPGD | |
| SCHEMBL6994527 | 1.00 | SIGMAR1 (0.36) | SIGMAR1HCRTR2HCRTR1LMNAHPGD | |
| SCHEMBL1222781 | 1.00 | SIGMAR1 (0.36) | SIGMAR1HCRTR2HCRTR1LMNAHPGD | |
| SCHEMBL3180941 | 0.82 | L3MBTL1 (0.37) | SIGMAR1HCRTR2HCRTR1LMNAHPGD | |
| SCHEMBL6987664 | 0.81 | SIGMAR1 (0.39) | SIGMAR1HCRTR2HCRTR1TMEM97POLB | |
| SCHEMBL6988972 | 0.79 | SIGMAR1 (0.38) | SIGMAR1HCRTR2HCRTR1HPGDGAA | |
| SCHEMBL1634186 | 0.73 | GAA (0.45) | SIGMAR1LMNAHPGDACP3TBXA2R | |
| SCHEMBL1634184 | 0.73 | GAA (0.45) | SIGMAR1LMNAHPGDACP3TBXA2R | |
| SCHEMBL27837886 | 0.73 | GAA (0.45) | SIGMAR1LMNAHPGDACP3TBXA2R | |
| SCHEMBL14366914 | 0.72 | L3MBTL1 (0.39) | SIGMAR1HCRTR2HCRTR1TBXA2RL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049543-B1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | CALLAGHAN INNOVATION RES LTD (NZ) | 2014-11-05 | — | — | EP | disclosed |
| US-8383636-B2 | Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-02-26 | — | — | US | disclosed |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | MTAP, PNP, TYMP | SIGMAR1 3219/4885HCRTR2 4591/4885HCRTR1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.